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Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative dementia characterized by amyloid
plaque accumulation, synapse/dendrite loss, and cognitive impairment. Transgenic mice
expressing mutant forms of amyloid-β precursor protein (AβPP) and presenilin-1 (PS1)
recapitulate several aspects of this disease and provide a useful model system for studying
elements of AD progression. AβPP/PS1 mice have been previously shown to exhibit behavioral
deficits and amyloid plaque deposition between 4–9 months of age. We crossed AβPP/PS1
animals with mice of a mixed genetic background (C57BL/6 × 129/SvJ) and investigated the
development of AD-like features in the resulting outcrossed mice. The onset of memory-based
behavioral impairment is delayed considerably in outcrossed AβPP/PS1 mice relative to inbred
mice on a C57BL/6 background. While inbred AβPP/PS1 mice develop deficits in radial-arm
water maze performance and novel object recognition as early as 8 months, outcrossed AβPP/PS1
mice do not display defects until 18 months. Within the forebrain, we find that inbred AβPP/PS1
mice have significantly higher amyloid plaque burden at 12 months than outcrossed AβPP/PS1
mice of the same age. Surprisingly, inbred AβPP/PS1 mice at 8 months have low plaque burden
suggesting that plaque burden alone cannot explain the accompanying behavioral deficits.
Analysis of AβPP processing revealed that elevated levels of soluble Aβ correlate with the degree
of behavioral impairment in both strains. Taken together, these findings suggest that animal
behavior, amyloid plaque deposition, and AβPP processing are sensitive to genetic differences
between mouse strains.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the most common
cause of dementia among the elderly. AD is characterized by aberrant production of
amyloid-β (Aβ) peptide and accumulation of Aβ-containing amyloid plaques in the brains of
affected individuals. AD patients exhibit distinct cognitive deficits, including memory loss,
poor judgment, and compromised spatial awareness. These cognitive impairments likely
result from underlying processes that occur during AD progression, including disruption of
synaptic connectivity (Coleman et al., 2004; Lassmann et al., 1993), alteration of dendrite
morphology (Anderton et al., 1998), and degeneration of brain structures (McEvoy et al.,
2009; Uylings and de Brabander, 2002).
Structural degeneration of the hippocampus and cortex occurs early in the course of AD, and
progressive impairment of these structures accompanies cognitive decline in this disease
(Hampel et al., 2008). During AD, amyloid plaques form throughout the forebrain,
becoming particularly abundant within the dentate gyrus molecular layer and temporal
cortex (Braak and Braak, 1991; Hellström-Lindahl et al., 2009). The forebrain is also a
major site of synapse loss and dendrite atrophy in AD, suggesting that synaptic connectivity
is altered within this region (Flood et al., 1987; Hanks and Flood, 1991; Scheff et al., 2007;
Scheff et al., 1996). Furthermore, hippocampal volume loss and cortical thinning both
correlate with memory impairment in AD (Du et al., 2007; Van Petten, 2004).
Mutations in the genes encoding amyloid-β precursor protein (AβPP) or proteins involved in
AβPP processing, such as presenilin-1 (PS1) and presenilin-2 (PS2), have been implicated
as causal factors in familial AD (Bertram and Tanzi, 2008). The development of transgenic
AD model mice based on these mutations has greatly facilitated research into the molecular
mechanisms of AD (Price et al., 1998; Ryman et al., 2006). While expression of one mutant
transgene reproduces several aspects of AD, co-expression of multiple transgenes has been
widely used as a strategy to boost Aβ production and accelerate the onset of AD-like
pathology in mice (Borchelt et al., 1997; Citron et al., 1997; Holcomb et al., 1998; Van
Dorpe et al., 2000). Double transgenic AβPP/PS1 mice exhibit extensive amyloid plaque
formation by 6 months that further increases with age (Garcia-Alloza et al., 2006;
Jankowsky et al., 2004). AβPP/PS1 mice display poor performance in spatial learning tasks
by 7 months with radial-arm water maze deficits arising as early as 4 months (Park et al.,
2006; Reiserer et al., 2007). AβPP/PS1 mice show deficiencies in novel object recognition
by 9 months (McClean et al., 2011). Dramatic reductions in brain weights and survival rates
have also been observed for AβPP/PS1 mice (Delatour et al., 2006; Gimbel et al., 2010;
Halford and Russell, 2009; Pugh et al., 2007).
As part of longer-term genetic studies to investigate the downstream effects of Aβ
overproduction, we crossed AβPP/PS1 mice with wild type (WT) mice of a mixed genetic
background (C57BL/6 × 129/SvJ) and investigated the development of AD-like features in
the resulting mice. We found that the onset of a behavioral deficit in radial-arm water maze
occurred between 16 and 18 months for outcrossed AβPP/PS1 mice, and we did not detect a
defect in novel object recognition at 18 months for these mice. Strikingly, inbred C57BL/6
AβPP/PS1 mice have defects in both tasks as early as 8 months. Additionally, we found that
amyloid plaque deposition was sparse at 12 months in outcrossed AβPP/PS1 mice, but
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increased significantly by 18 months in regions of the hippocampus and cortex. Inbred
C57BL/6 AβPP/PS1 mice have significantly higher plaque deposition at 12 months than
outcrossed AβPP/PS1 mice at this same age, but have low plaque levels at 8 months.
Importantly, we found that the degree of behavioral impairment coincides with increases in
levels of soluble Aβ levels in both strains. Together, these results suggest that AD-like
behavioral impairment and pathology develop considerably later in the outcrossed AβPP/
PS1 transgenic mice than in AβPP/PS1 transgenic mice on an inbred C57BL/6 genetic
background.
Materials and Methods
Animal use and general procedures
AβPP/PS1 mice (AβPPswe, PS1-1ΔE9) of mixed genetic background (C57BL/6 × C3H/
HeJ) (Jankowsky et al., 2001) were bred with WT mice of a different mixed genetic
background (C57BL/6 × 129/SvJ) (Koleske et al., 1998). The resulting outcrossed mice
were propagated by inbreeding non-sibling pairs of WT and hemizygous AβPP/PS1 mice.
AβPP/PS1 mice of inbred genetic background (C57BL/6) were generated by extensively
backcrossing (>10 generations) AβPP/PS1 mice of mixed genetic background (C57BL/6 ×
C3H/HeJ) onto the C57BL/6 background, as described previously (Gimbel et al., 2010). The
C57BL/6 transgenic line was maintained on this background separate from outcrossed
AβPP/PS1 mice. AβPP/PS1 animals used in these studies had copies of both the AβPP and
PS1 transgenes, and WT littermates were used as controls for all experiments. Animal
genotypes were determined using a PCR reaction detecting both transgenes, and genotypes
were confirmed at death. Both male and female animals were used for experiments.
Experiments comparing WT and AβPP/PS1 mice were conducted and scored by an
experimenter blinded to animal genotype. For behavioral experiments, mice were handled 5
min each for 5 days prior to the experiment to habituate them to the tester and testing room.
For experiments requiring heavy sedation, animals were administered Nembutal via
intraperitoneal injection prior to the experiment. All procedures were compliant with federal
regulations and approved by the Yale University Animal Care and Use Committee. Data
from all experiments were analyzed using Prism software (GraphPad, San Diego, CA).
Amyloid plaque deposition
Sedated animals were transcardially perfused with 0.1M PBS pH 7.4, followed by 4%
paraformaldehyde/PBS. Excised brains were postfixed in 4% paraformaldehyde/PBS
overnight at 4°C, then cryoprotected in 30% sucrose/PBS overnight at 4°C. Horizontal
sections (50 µm) were cut on a sliding-freezing microtome, mounted on gelatin-coated
slides, and dehydrated overnight at room temperature. Dried sections were stained for
amyloid plaques with fresh, filtered 1% Thioflavin S (T1892; Sigma) as follows: ddH2O,
2×2 min; 1% Thioflavin S, 60 min; 70% ethanol, 5 min; ddH2O, 2×2 min. Coverslips were
mounted with anti-fade medium (2% n-propyl gallate, 80% glycerol/PBS), and phase and
green fluorescent images of the hippocampus were acquired on a Nikon TE2000-S
microscope with NIS-Elements software (Nikon) at 4× magnification. Images were stored as
NIS-Elements files (.nd2) and analyzed for plaque deposition as described below.
Representative images shown in Figures 3 and 4 were obtained using NIS-Elements
software to crop, view scale bar, convert green fluorescent images to black-and-white, and
increase contrast slightly for better representation. Images shown for each strain and age
were obtained using identical manipulations in NIS-Elements.
Amyloid plaque deposition was quantified using ImageJ software (NIH). TIFF images were
converted to 8-bit grayscale, hippocampal and cortical subregions (as defined by (Franklin
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and Paxinos, 2008)) were demarcated on the phase images, and subregion boundaries were
applied to the fluorescent images. Each subregion was processed with a custom macro that
measured the subregion area, inverted the grayscale spectrum, applied a thresholding
function, and employed particle analysis to select and measure amyloid plaque areas. Within
the hippocampus, the CA1 stratum radiatum, CA1 stratum oriens, CA3 stratum radiatum,
CA3 stratum oriens, and dentate gyrus molecular layer subregions were quantified
independently and plaque burden values were combined to obtain a weighted average for
overall hippocampal plaque burden. Mean values for amyloid plaque burden was calculated
for each mouse and analyzed by Kruskal-Wallis tests, followed by Mann-Whitney post-tests
for significance.
Radial-arm water maze
The radial-arm water maze testing protocol was based on (Alamed et al., 2006), including
modifications from (Park et al., 2006). The maze consisted of an inflatable pool 1.2 m in
diameter with six 18 cm wide swim alleys radiating from a 35 cm wide central area. Spatial
cues 60 cm tall were placed on the walls of the room adjacent to the end of each arm. A
hidden escape platform was submerged at the end of the goal arm, which remained constant
for each mouse across trials. The main task consisted of six learning blocks of five trials
spread equally over two consecutive days. For each trial, the animal was placed into a start
arm and allowed to swim to the escape platform. Start arms were assigned semi-randomly so
that all five non-goal arms were represented during each learning block. After entering an
incorrect arm or failing to select an arm for 1 min, the mouse was returned to the start arm
and charged an error. Each trial ended when the animal either located the platform or
committed six errors, at which point it was guided to the platform. Once on the platform, the
animal was left for 15 sec before being returned to its cage.
Two measurements were taken to account for potential differences between genotypes in
escape motivation, swimming ability, and vision. First, during the main task, the time was
recorded for each excursion that occurred during the first five trials. An excursion was
defined as the individual period from when the animal is placed in the start arm to when it
either commits an error or locates the escape platform. Second, following the main task, the
maze was modified so that the non-goal and non-start arms were blocked. Animals were
placed into the start arm, and escape latency was timed for each of the five start arms.
For 12-month outcrossed animals, a reversal task consisting of three learning blocks of four
trials was administered the day after the main task. A new goal arm located at least two arms
away from the previous goal arm was assigned randomly for each mouse and remained
constant across reversal trials. Start arms, which excluded the previous and current goal
arms, were assigned semi-randomly so that all four remaining arms were represented during
each learning block. The reversal task was conducted similarly to the main task, and mice
were scored for total errors. A perseverant error was additionally scored when an animal
entered its previous goal arm.
For total errors and escape latencies, mean values for each learning block were calculated
for each mouse and analyzed by two-factor ANOVAs (genotype × trial) with repeated
measures (trial), followed by post hoc Student’s t-tests for significance.
Novel object recognition
The novel object recognition testing protocol was based on (Frick and Gresack, 2003),
including adaptations from (Sfakianos et al., 2007). On the last day of pre-test handling,
animals were habituated to the empty testing arena (45 cm × 24 cm × 20 cm) for 30 min.
The following day, two identical objects (rubber ducks, bottle caps, or conical tubes) were
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placed into the testing arena, and the animals were allowed to amass 30 sec of total object
exploration. Two days later, one familiar object was placed into the arena with one novel
object, and the animals were allowed to amass 30 sec of total object exploration. The type
and location of the novel object was counterbalanced between mice. The sample and choice
phases were video recorded and scored for object exploration, defined as time spent in
directed nasal or oral contact with the objects. Exploration times for each mouse were
analyzed by two-factor ANOVAs (genotype × object), followed by post hoc Student’s t-tests
for significance.
Animal survival
Outcrossed animals were monitored over a period of 18 months for survival. Animal deaths
were only counted if they could not be attributed to other causes, such as disease or
aggression-related injury. Kaplan-Meier curves for each genotype were generated by
calculating the cumulative percent of animals surviving to each month. Animal survival
curves were analyzed using the Mantel-Haenszel log-rank test for significance.
Brain tissue collection and immunoblot analysis
Protein levels were determined using a previously described protocol (Gimbel et al., 2010).
Briefly, mice were sacrificed and perfused with ice-cold 0.1M PBS pH 7.4 for 2 min. Each
brain was extracted, and the right hemisphere was homogenized in TBS (50 mM Tris, 150
mM NaCl, pH 7.6) containing a protease inhibitor cocktail (Thermo Scientific, Rockford,
IL). Tissue was homogenized using a Polytron tissue disruptor (Kinematica, Bohemia, NY),
homogenates were centrifuged at 100,000 ×g for 20 min at 4°, and supernatants were frozen
for subsequent analysis of the soluble fraction. Pellet fractions were then resuspended in
TBS with 2% Triton X-100, 0.1% SDS, and the protease inhibitor cocktail, homogenized,
and centrifuged at 100,000 ×g for 20 min at 4°. Supernatants were frozen for subsequent
analysis of the detergent-soluble fraction. The final detergent-insoluble pellet was
resuspended in 0.1M formic acid, homogenized, and centrifuged at 100,000 ×g for 20 min at
4° to obtain the insoluble fraction. Prior to freezing, the insoluble fraction samples were
neutralized with 1M Trizma-base. Lysate samples were run on SDS-PAGE gels or pre-cast
10–20% Tris-tricine gels (BioRad), transferred to nitrocellulose membranes, and probed
with antibodies to the following proteins: full length AβPP, soluble AβPPα (sAβPPα),
AβPP β-C-terminal fragment (β-CTF), soluble Aβ (sAβ), insoluble Aβ, presenilin-1 (PS1),
HSP70, and actin (Table 1). Immunoblots were quantified using Quantity One software
(Bio-Rad), and protein signals were normalized to loading control levels (HSP70 or actin).
Mean expression levels were analyzed with Kruskal-Wallis tests followed by post hoc
Mann-Whitney tests for significance.
Antibody characterization
The rabbit anti-AβPP polyclonal antibody specifically recognizes residues 695, 751, and 770
of the human form of AβPP. This antibody detects a ~110 kDa band in immunoblots of
transgenic AβPP/PS1 mouse brain lysates.
The mouse anti-AβPP (6E10) antibody specifically recognizes the human form of AβPP.
This antibody detects an ~100 kDa band in immunoblots of transgenic AβPP/PS1 mouse
brain lysates as the sAβPPα cleavage product. This antibody recognizes soluble and
insoluble Aβ peptide (~3.8 kDa) on immunoblots from gradient gels optimized for detection
of small proteins. This antibody also recognizes the AβPP β-C-terminal fragment (~16 kDa)
from detergent-extracted mouse brain lysates.
The rabbit anti-PS1 polyclonal antibody specifically recognizes the human form of PS1.
This antibody detects the ~22 kDa PS1 C-terminal fragment in immunoblots of transgenic
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AβPP/PS1 mouse brain lysates. Additionally, this antibody detects full length PS1 protein at
~55 kDa to a lesser extent.
Antibodies to HSP70 (5A5), and actin (C4) were used as loading controls. The mouse anti-
HSP70 antibody recognizes the murine form of HSP70 and detects an ~70 kDa band in
immunoblots of mouse brain lysates. The mouse anti-actin antibody recognizes the murine
form of actin and detects an ~42 kDa band in immunoblots of mouse brain lysates.
Results
Inbred C57BL/6 AβPP/PS1 mice have an earlier onset of radial-arm water maze deficits
than outcrossed mice
To determine if and when AβPP/PS1 mice exhibit deficits in forebrain function, we tested
them at different ages in a radial-arm water maze using a protocol previously shown to
detect spatial learning and reference memory defects in AD transgenic mice (Alamed et al.,
2006; Park et al., 2006; Wilcock et al., 2006). For this task, animals placed into one arm of a
six-arm water maze used spatial cues located on the walls of the testing room to locate a
hidden platform, which remained constant for each animal across 30 trials (Fig. 1A). An
error was charged each time an animal entered an incorrect arm or failed to select an arm
after 1 min. Errors due to failing to select an arm comprised only two percent of all errors
and mostly occurred during the first two learning blocks.
At 12 months, there were no significant differences in water maze performance between WT
and AβPP/PS1 outcrossed animals (Fig. 1C). There was a main effect of trial, indicating that
animal performance improved across successive trials, as they went from making 4 errors
per trial in the first five trials to only 1 error per trial in the last five trials. At 16 months,
outcrossed AβPP/PS1 mice do not perform significantly different than their WT
counterparts (Fig. 1D). These results were striking as previously published work measured
behavioral impairments in AβPP/PS1 mice as early as 9 months (Park et al., 2006). By 18
months, outcrossed AβPP/PS1 animals performed significantly worse in the radial-arm
water maze than WT animals, maintaining a rate of 3 errors per trial for their last 15 trials,
while WT mice improved to 1 error per trial during that same time (Fig. 1E). These results
indicate that outcrossed AβPP/PS1 mice have a significant delay in behavioral impairment
relative to previously published reports (Garcia-Alloza et al., 2006; McClean et al., 2011;
Park et al., 2006).
We hypothesized that the delayed behavioral phenotype could be due to genetic elements
introduced during the initial outcrossing. Therefore, we measured radial-arm water maze
behavior in inbred C57BL/6 AβPP/PS1 mice at an earlier age. Inbred AβPP/PS1 mice
perform significantly worse than their WT littermates at 8 months, maintaining a rate of 2
errors per trial for the last 15 trials, while WT mice make on average less than 1 error per
trial during this same time (Fig. 1F). These results indicate that outcrossed AβPP/PS1 mice
are delayed in their development of behavioral deficits relative to their inbred C57BL/6
AβPP/PS1 counterparts.
Two measurements were taken to account for potential differences between genotypes in
escape motivation, swimming ability, and vision. During the main task, each time the animal
was placed in the start arm, we determined how long it took for it to make an excursion
(either make an error or locate the platform), which could reveal if an animal was unequally
motivated to perform the task. There were no differences between genotypes for any of the
experimental groups during the first 5 trials (Fig. 1B). Following the main task, the maze
was modified so that non-goal arms were blocked, and the animal needed only to traverse a
closed channel to reach its goal arm. For five trials, there were no significant differences
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between genotypes in escape latencies for outcrossed 12-month mice (WT, 14 ± 2 sec versus
AβPP/PS1, 14 ± 1 sec; mean ± SE; Student’s t-test, p = 0.90), outcrossed 18-month mice
(WT, 17 ± 4 sec versus AβPP/PS1, 23 ± 4 sec; p = 0.28), or inbred C57BL/6 8-month mice
(WT, 8.9 ± 2 sec versus AβPP/PS1, 9.9 ± 2 sec; p = 0.74). Together, these results suggest
that the poor performance of outcrossed AβPP/PS1 animals at 18 months and inbred AβPP/
PS1 mice at 8 months cannot be attributed to reduced escape motivation, swimming ability,
or vision.
Since both genotypes in outcrossed mice learned the task similarly at 12 months, we also
tested behavioral flexibility with a reversal task in which the location of the goal platform
was changed. For an animal to succeed in this reversal task, it must be able to remember the
new platform location as well as inhibit its inclination to return to the previous goal arm.
WT and AβPP/PS1 animals performed similarly in the reversal task when scored for either
total errors or perseverant errors (returns to the previous goal arm) (Fig. 1G and 1H). There
were main effects of trial for both total errors and perseverant errors, signifying that animal
performance improved across reversal trials.
Inbred C57BL/6 AβPP/PS1 mice have an early deficit in novel object recognition while
outcrossed animals show no deficit in novel object recognition
To assess the degree of functional impairment of the outcrossed strain at 18 months, we
tested AβPP/PS1 mice in a novel object recognition task. Novel object recognition requires
proper hippocampal function, but lacks the spatial challenge of the radial-arm water maze
(Clark et al., 2000; Zola et al., 2000). We followed a protocol used previously to detect
deficits in animals with hippocampal impairment (Sfakianos et al., 2007). This task takes
advantage of the innate tendency mice have to explore novel objects placed into familiar
environments. During the sample phase, the animal is allowed to become familiar with two
identical objects (Fig. 2A). During the choice phase, which takes place 48 hours later, the
animal is presented with a familiar object and a novel object, and the time the animal spends
exploring each object is measured.
During the sample phase, we found that 18-month-old outcrossed WT and AβPP/PS1
animals explored both familiar objects for equivalent amounts of time (Fig. 2B). During the
choice phase, WT animals spent significantly more time exploring the novel object than the
familiar one, as expected (Fig. 2C). Outcrossed AβPP/PS1 mice also spent significantly
more time exploring the novel object, indicating that they do not have a deficit
discriminating the novel object from the familiar one. Thus, while outcrossed AβPP/PS1
mice have a clear deficit in radial-arm water maze performance, they are still able to
perform a novel object recognition task at 18 months.
We then tested 8-month inbred C57BL/6 WT and AβPP/PS1 animals in the novel object
recognition task. We found that during the sample phase each genotype explored both
familiar objects equally (Fig. 2D). During the choice phase, while inbred WT mice spend
significantly more time with the novel object as expected, inbred AβPP/PS1 mice do not
spend more time exploring the novel object (Fig. 2E). These results indicate that inbred
AβPP/PS1 mice fail to discriminate the novel from the familiar object at 8 months and that
genetic elements present in the outcrossed strain may help protect outcrossed AβPP/PS1
mice from developing defects in novel object recognition.
Inbred C57BL/6 AβPP/PS1 mice have higher amyloid plaque burden than outcrossed mice
To better understand the timing and extent of neurodegeneration in outcrossed AβPP/PS1
animals, we analyzed amyloid plaque deposition at 12 and 18 months. To visualize amyloid
plaques, we stained brain sections from WT and AβPP/PS1 mice with the amyloid-binding
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dye Thioflavin S (Westermark et al., 1999). We quantified overall plaque burden in various
subfields of the hippocampus, including the CA1 stratum radiatum and stratum oriens, the
CA3 stratum radiatum and stratum oriens, and the dentate gyrus molecular layer (Fig. 3A).
We then combined the plaque burden from each region to obtain a value for total
hippocampal plaque burden (Fig. 3B), which is a function of both plaque density and plaque
size. At 12 months, we found that the AβPP/PS1 hippocampus had only sparse amyloid
plaques (Fig. 3C), while by 18 months amyloid plaque deposition had increased
dramatically (Fig. 3D). WT mice did not have any detectable amyloid deposition at either of
these ages (data not shown). Similarly, when we quantified plaque burden within another
brain region, the temporal cortex, outcrossed AβPP/PS1 transgenic mice had low amyloid
plaque burden at 12 months, which significantly increased by 18 months (Fig. 4B-D).
Consistent with the behavioral measurements, the development of AD-like pathology in
outcrossed AβPP/PS1 mice is delayed considerably relative to published phenotypes, which
display robust amyloid plaque deposition and behavioral impairments as early as 9 months
(Garcia-Alloza et al., 2006; McClean et al., 2011; Park et al., 2006). We hypothesized that
the delayed phenotype may be due to genetic elements introduced during the initial
outcrossing. Therefore, we compared plaque deposition in the hippocampus and cortex of
outcrossed AβPP/PS1 mice to AβPP/PS1 mice on a uniform C57BL/6 background at both 8
and 12 months. In both the hippocampus (Fig. 3B and 3F) and cortex (Fig. 4B and 4F),
inbred mice had higher plaque burden at 12 months than outcrossed mice of the same age.
Interestingly, 8-month-old inbred AβPP/PS1 mice have low hippocampal and cortical
plaque burden (Fig. 3E and 4E). Thus, while outcrossed mice have a delayed onset of plaque
deposition, this is not sufficient to explain their delayed behavioral deficits, as 8-month-old
inbred mice also have low amyloid plaque burden, yet display significant behavioral
impairments.
Normal brain weight, body weight, and survival in outcrossed AβPP/PS1 mice
During the course of our studies, we recorded gross body parameters and survival rates for
the outcrossed AβPP/PS1 mice. Brain weight reductions of 10 percent and body weight
reductions of 30–40 percent have been reported for aged AβPP/PS1 mice (Delatour et al.,
2006; Pugh et al., 2007). We found no differences in brain weight, body weight, or brain/
body weight ratios in outcrossed AβPP/PS1 mice compared to WT mice at 18 months
(Table 2). Furthermore, reduced survival rates have also been documented in inbred AβPP/
PS1 mice (Gimbel et al., 2010; Halford and Russell, 2009), possibly due to neuron
hyperexcitability and epileptic seizures (Minkeviciene et al., 2009; Palop et al., 2007). In our
study, outcrossed AβPP/PS1 animals showed no differences from WT animals in survival
rates up to 18 months (Fig. 5A). Only one outcrossed animal in our study was witnessed to
be having a seizure, but this was a WT animal.
Soluble Aβ levels are increased in inbred C57BL/6 transgenic mice compared to
outcrossed mice
Based on the reduced amyloid plaque burden observed in outcrossed AβPP/PS1 mice, we
wanted to determine if the levels of AβPP and its various processed forms were different in
these mice. Since 8-month inbred AβPP/PS1 mice display a strong behavioral deficit despite
a low overall plaque burden in both the hippocampus and cortex, we hypothesized that these
mice may have differences in AβPP transgene expression or processing that would not be
detectable by histological staining methods. In particular, soluble Aβ species are thought to
play a toxic role in AD and have been shown to correlate with levels of cognitive
impairment in AD transgenic mice (Zhang et al., 2011). First, we measured levels of full
length AβPP by immunoblot in fractionated brain lysate from outcrossed AβPP/PS1 mice at
12 and 18 months and inbred C57BL/6 AβPP/PS1 mice at 8 and 12 months. We found that
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full length AβPP expression increases with age in both transgenic strains, with 12-month
inbred AβPP/PS1 mice showing a robust increase above each of the other groups (Fig. 5B
and 5G). Full length AβPP is processed by one of two secretase pathways, which produce
different soluble and membrane-bound cleavage products (O’Brien et al., 2001). We
quantified the levels of three cleavage products from these same samples. Soluble AβPPα is
released after cleavage of full length AβPP by the α-secretase complex. We found no
differences in soluble AβPPα levels in outcrossed transgenic mice relative to their inbred
counterparts at any age (Fig. 5C and 5G). Full length AβPP can also be processed first by
the β-secretase complex, which produces a membrane-associated C-terminal fragment (β-
CTF). This fragment is subsequently cleaved by the PS1-containing γ-secretase complex,
leading to the production of soluble Aβ peptide, which can aggregate to form toxic soluble
species and insoluble amyloid plaques. The levels of the β-CTF and PS1 from detergent
solubilized extracts are unchanged across each strain and age (Fig. 5D and 5H). Soluble Aβ
levels increase with age in both outcrossed and inbred mice and are significantly higher in 8-
month inbred mice compared to 12-month outcrossed mice (Fig. 5E and 5H), which mirrors
the differential impairments in behavioral tasks we observed in these two mouse
populations. Consistent with Thioflavin S staining of insoluble plaques, 12-month
outcrossed and 8-month inbred transgenic mice have low insoluble Aβ levels, while both
18-month outcrossed mice and 12-month inbred mice have significantly higher insoluble Aβ
levels (Fig. 5F and 5H).
Discussion
AD is characterized by distinct features including high levels of amyloid plaque formation,
progressive cognitive impairment, widespread synapse/dendrite loss, and atrophy in selected
brain regions. Transgenic mice expressing mutant forms of AβPP and PS1 have proven
useful for investigating the molecular mechanisms that give rise to these clinical features.
We crossed AβPP/PS1 mice with mice of a mixed genetic background (C57BL/6 × 129/SvJ)
and investigated the development of AD-like pathology in the resulting mice. While we did
reproduce many of the phenotypes reported for expression of these transgenes, we found
that the onset of these traits was delayed considerably in the outcrossed mice relative to
AβPP/PS1 mice on an inbred C57BL/6 background.
In the radial-arm water maze, outcrossed AβPP/PS1 mice performed similarly to WT mice
at 12 and 16 months, but develop a clear deficit by 18 months. This onset of impairment is
delayed considerably relative to other AβPP/PS1 mouse studies. Park et al. (2006) measured
radial-arm water maze performance in mice expressing the same AβPP/PS1 transgenes on a
mixed genetic background (C57BL/6 × C3H/HeJ) using a very similar protocol for animals
between 4–13 months. In this study, AβPP/PS1 animals made more errors at 8 months than
mice in this study did at 12 months and made as many errors at 10 months as the mice in this
study did at 18 months. Our finding that inbred C57BL/6 AβPP/PS1 mice develop water
maze deficits as early as 8 months further supports our hypothesis that the delayed onset of
behavioral deficits is due to differences in strain background.
To determine the extent of functional impairment at 18 months, we tested outcrossed AβPP/
PS1 mice in a hippocampal-dependent novel object recognition task. Outcrossed AβPP/PS1
mice are able to discriminate between the novel and familiar objects and perform this task
similarly to WT animals. Using a similar hippocampal-dependent protocol, McClean et al.
(2011) found that C57BL/6 mice expressing the same AβPP/PS1 transgenes had a deficit in
novel object recognition as early as 9 months. We found that C57BL/6 AβPP/PS1 mice have
deficits in novel object recognition at 8 months, further supporting the idea that genetic
elements in the outcrossed AβPP/PS1 mice are likely responsible for the stark behavioral
differences.
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A discrepancy for the outcrossed mice exists in their differential success at 18 months in
novel object recognition and the radial-arm water maze, both of which have been shown to
depend on hippocampal function (Clark et al., 2000; Diamond et al., 1999). An important
difference between these two behavioral tasks is that novel object recognition lacks the
spatial element of the radial-arm water maze. Within the hippocampus, dentate gyrus
granule neurons have been shown to play a critical role in spatial behavior, but these same
neurons are not required for novel object discrimination (Lee et al., 2005; Xavier and Costa,
2009). Thus, it is possible that functional impairment in the outcrossed mice is restricted to
particular regions that affect spatial behavior, but has not yet affected neurons in the dentate
gyrus needed for novel object recognition.
Outcrossed AβPP/PS1 mice had minimal amyloid plaque deposition at 12 months, but
overall plaque burden increased significantly by 18 months in regions of the hippocampus
and cortex. We found that inbred C57BL/6 AβPP/PS1 mice have a significantly higher
plaque burden at 12 months compared to outcrossed mice in all brain regions examined.
While quantification of amyloid plaques is sensitive to differences in staining protocols and
scoring methods, plaque measurements by other groups corroborate our finding that plaque
deposition is delayed in outcrossed AβPP/PS1 mice relative to other mice expressing the
same transgenes. Garcia-Alloza et al. (2006) reported on the development of amyloid
plaques in AβPP/PS1 mice between 4–12 months using Thioflavin S in a mixed C57BL/6 ×
C3H/HeJ strain background. At 12 months, they found plaque density and plaque burden to
be roughly ten-fold higher than the outcrossed mice from our study at that same age, but on
par with values we measure at 18 months. They also found that plaque size remained
constant between 6 and 12 months with areas similar to outcrossed mice, suggesting that the
staining and imaging procedures used were comparable. Taken together with these previous
results, our comparison between inbred and outcrossed transgenic strains suggests that the
delayed plaque deposition we observed in outcrossed mice is due to differences in strain
background, particularly genetic elements of the 129/SvJ strain. Interestingly, we found that
8-month C57BL/6 AβPP/PS1 mice had low amyloid plaque deposition, despite having
significant behavioral impairments. These results indicate that while plaque deposition is
delayed in outcrossed mice, it cannot fully account for their late behavioral impairment.
During the course of this study, we recorded brain weights, body weights, and survival rates
for AβPP/PS1 mice. We found brain and body weight values to be normal in outcrossed
AβPP/PS1 mice. In contrast, Delatour et al. (2006) noted a 10 percent decrease in total brain
weight and a 40 percent reduction in body weight in aged AβPP/PS1 mice bearing different
mutations on a primarily C57BL/6 background. We also observed that only 10 percent of
outcrossed AβPP/PS1 mice died before 12 months, which was nearly identical to WT
mortality rates. Conversely, using the same line of inbred AβPP/PS1 animals as in the
current study, Gimbel et al. (2010) found animal survival to be drastically shortened with
over 50 percent of their transgenic mice dying by 12 months. Thus, for both brain/body
weight and survival, the dramatic phenotypes seen in other reports are not recapitulated in
the outcrossed AβPP/PS1 line.
Based on our own measurements and comparisons with other studies, there appear to be
considerable discrepancies between the phenotypes of inbred and outcrossed AβPP/PS1
mice. In some cases, this disparity might be attributed to differences in the specific
mutations used in the AβPP and PS1 transgenes, although the lack of carryover for such
remarkable effects is surprising. In other cases, including this study, the same mutant AβPP
and PS1 transgenes were expressed and the only major difference in these mice was the
genetic background on which the transgenes were expressed. The effects of AD transgene
expression have been shown previously to differ with strain background (Crawley, 1999;
Ryman et al., 2006). For example, mutant AβPP expressed on an inbred C57BL/6
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background produced robust amyloid plaque formation and deficits in Morris water maze
performance, but FVB/N mice expressing the same transgene showed no plaque formation
and early lethality (Hsiao et al., 1996; Hsiao et al., 1995). Additionally, inbred C57BL/6
AβPP transgenic mice have higher amyloid plaque deposition than AβPP transgenic mice of
either an A/J or a mixed C57BL/6 × DBA/2 genetic background (Ozmen et al., 2007;
Sebastiani et al., 2006). Strain background has also been shown to have a strong influence
on the performance of AβPP transgenic mice in a variety of behavioral assays (Glazner et
al., 2010; Lassalle et al., 2008; Rustay et al., 2010).
The primary genetic element introduced by our initial outcrossing was the presence of the
129/SvJ genetic background. Interestingly, 129/SvJ mice harboring mutant AβPP transgenes
have been shown previously to exhibit reduced AβPP processing as well as resistance to
AβPP transgene-induced early lethality (Krezowski et al., 2004; Lehman et al., 2003). Based
on our findings that amyloid plaques levels do not correlate with behavioral impairment, we
hypothesized that the delayed behavioral phenotypes could be due to differences in AβPP
production or processing. We found that full length AβPP levels increase with age in both in
outcrossed and inbred AβPP/PS1 mice. Processing of full length AβPP via the non-
amyloidogenic α-secretase pathway is not affected by strain or age based on soluble AβPPα
levels. Full length AβPP is also processed via an amyloidgenic pathway, mediated by β-
secretase and PS1-containing γ-secretase complexes (O’Brien et al., 2001). We found that
soluble Aβ increases with age in each strain and that soluble Aβ levels mirror the degree of
behavioral impairment in both strains. We found low insoluble Aβ levels in 8-month
C57BL/6 mice when compared to 18-month outcrossed mice or 12-month inbred mice,
indicating that while soluble Aβ is produced at high levels in 8-month inbred mice, it is not
efficiently incorporated into insoluble plaques.
The presence of soluble Aβ species prior to amyloid plaque formation has been associated
with synaptic impairment and cognitive decline associated with Alzheimer’s disease (Hsia,
et al., 1999; Mucke, et al., 2000). Additionally, soluble Aβ oligomers have toxic effects on
neurons when introduced in culture (Um, et al., 2012; Walsh, et al., 2002). In our study, we
found that 8-month C57BL/6 mice have a low overall plaque burden, yet significant
behavioral impairments in memory tasks. One explanation for this discrepancy is that inbred
mice express high levels of soluble Aβ, which may lead to impaired neuronal signaling and
subsequent behavioral deficits. Based on our findings, we conclude that soluble Aβ levels
represent the major pathological difference between these strains. However, 129/SvJ mice
also show greater resistance to various neural insults, including ischemia and spinal cord
injury (Dimou et al., 2006; Fujii et al., 1997; Wellons et al., 2000). Thus, the delayed
phenotypes observed in the outcrossed AβPP/PS1 mice in this study could be the product of
differences in both soluble Aβ levels and decreased susceptibility of the 129/SvJ strain to
neural insult.
In conclusion, we crossed AβPP/PS1 mice with mice of a mixed genetic background and
investigated the development of AD-like features in the resulting mice. We observed a
delayed onset of spatial learning impairment and amyloid plaque deposition in the
outcrossed mice, through both direct comparisons with an inbred C57BL/6 strain and
indirect comparisons to published reports of AβPP/PS1 mice on other genetic backgrounds.
Furthermore, the different level of soluble Aβ peptide present in these two strains provides a
potential mechanism underlying their behavioral differences. Strain background introduces a
potential confound for interpreting the effects of transgene expression across studies, and
these findings suggest that genetic elements present in certain mouse strains can
significantly delay the onset and severity of AD-like pathology and AD-related behaviors in
different transgenic mouse lines.
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Fig. 1.
Onset of radial-arm water maze deficit occurs between 16 and 18 months for outcrossed
AβPP/PS1 mice and as early as 8 months in inbred C57BL/6 AβPP/PS1 mice. (A) Diagram
of radial-arm water maze. Maze contained six arms with large visual cues positioned on the
walls of the room adjacent to the distal end of each arm. A hidden platform (HP) was
submerged at the end of one arm. (B) Controls assessing escape motivation, swimming
ability, and vision across trials in outcrossed WT and AβPP/PS1 mice at 12, 16, and 18
months and inbred C57BL/6 WT and AβPP/PS1 mice at 8 months. Symbols represent mean
seconds per excursion during first five trials ± SE. Two-factor ANOVAs (genotype ×
group): no interaction, F < 1. Errors made across trials by WT and AβPP/PS1 mice at (C-E)
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12, 16, and 18 months in outcrossed mice and (F) 8 months in inbred C57BL/6 mice.
Symbols represent mean errors made per trial during groups of five trials ± SE. Two-factor
ANOVAs (genotype × trial) with repeated measures (trial): 12 months outcrossed: main
effect of trial, F(5,27) = 22.08, p < 0.001; 16 months outcrossed: main effect of trial, F(5,10) =
15.63, p < 0.001; 18 months outcrossed: interaction, F(5,14) = 4.35, p < 0.01; 8 months
inbred C57BL/6: interaction, F(5,19) = 4.63, p < 0.001. Post hoc Student’s t-tests, *p < 0.05,
***p < 0.001. Excursion time and water maze analyses: 12 months outcrossed: WT, n = 15
mice; AβPP/PS1, n = 14 mice; 16 months outcrossed: WT, n = 5 mice; AβPP/PS1, n = 7
mice; 18 months outcrossed: WT, n= 8 mice; AβPP/PS1, n = 8 mice; 8 months inbred
C57BL/6: WT, n = 11 mice; AβPP/PS1, n = 10 mice. (G-H) Performance in radial-arm
water maze reversal does not differ between WT and AβPP/PS1 mice at 12 months. (G)
Total errors and (H) perseverant errors made per trial by WT and AβPP/PS1 mice during
reversal task at 12 months. Symbols represent mean errors made per trial during groups of
four trials ± SE. Two-factor ANOVAs (genotype × trial) with repeated measures (trial): total
errors: main effect of trial, F(2,27) = 29.36, p < 0.001; perseverant errors: main effect of trial,
F(2,27) = 15.09, p < 0.001. Water maze reversal analyses: 12 months: WT, n = 15 mice;
AβPP/PS1, n = 14 mice.
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Fig. 2.
Novel object recognition does not differ between outcrossed WT and AβPP/PS1 mice at 18
months while inbred C57BL/6 AβPP/PS1 mice have defects in this task at 8 months. (A)
Diagram of object placement during sample and choice phases. L = left object, R = right
object, F = familiar object, N = novel object. Object exploration times by outcrossed WT
and AβPP/PS1 mice at 18 months during the (B) sample phase and (C) choice phase. Bars
represent mean seconds spent exploring object ± SE. Two-factor ANOVAs (genotype ×
object): sample phase: no interaction, F < 1; choice phase: interaction, F(1,14) = 6.05, p <
0.05. Post hoc Student’s t-tests, **p < 0.01, ***p < 0.001. Object exploration times by
inbred C57BL/6 WT and AβPP/PS1 mice at 8 months during the (D) sample phase and (E)
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choice phase. Bars represent mean seconds spent exploring object ± SE. Two-factor
ANOVAs (genotype × object): sample phase: no interaction, F < 1; choice phase:
interaction, F(1,19) = 3.89, p < 0.05. Post hoc Student’s t-tests, ***p < 0.001. Novel object
recognition analyses: outcrossed mice: WT, n= 8 mice; AβPP/PS1, n = 8 mice; inbred
C57BL/6: WT, n = 11 mice; AβPP/PS1, n = 10 mice.
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Fig. 3.
Amyloid plaque burden increases significantly with age in outcrossed and inbred C57BL/6
AβPP/PS1 mouse hippocampus and is highest in 12-month inbred C57BL/6 mice. (A)
Diagram of mouse hippocampus showing regions scored for plaque deposition, adapted
from (Franklin and Paxinos, 2008). CA1 = CA1 region, CA3 = CA3 region, Rad = stratum
radiatum, Or = stratum oriens, DG = dentate gyrus, Mol = molecular layer. Scale bar = 200
µm. (B) Plaque burden in the AβPP/PS1 hippocampus in outcrossed mice at 12 and 18
months and in inbred C57BL/6 mice at 8 and 12 months. Bars represent means ± SE.
Kruskal-Wallis test: plaque burden: p < 0.01. Post hoc Mann-Whitney, *p < 0.05, **p <
0.01. Plaque deposition analyses: 12 months outcrossed, n = 5 mice (6 sections per mouse);
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18 months outcrossed, n = 8 mice (6 sections per mouse); 8 months inbred C57BL/6, n = 3
mice (6 sections per mouse); 12 months inbred C57BL/6, n = 6 mice (4–6 sections per
mouse). (C-F) Representative fluorescent images of Thioflavin S stained sections from the
AβPP/PS1 hippocampus at (C) 12 months in outcrossed mice, (D) 18 months in outcrossed
mice, (E) 8 months in inbred C57BL/6 mice, and (F) 12 months in inbred C57BL/6 mice.
Bright puncta indicate Thioflavin S -reactive amyloid deposits. Scale bars = 200 µm.
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Fig. 4.
Amyloid plaque burden increases significantly with age in outcrossed and inbred C57BL/6
mouse temporal cortex and is higher in inbred C57BL/6 mice than outcrossed mice at 12
months. (A) Diagram of mouse cortex showing region scored for plaque deposition, adapted
from (Franklin and Paxinos, 2008). TeA = temporal cortex, Ent = entorhinal cortex. Scale
bar = 200 µm. (B) Plaque burden in the temporal cortex in 12- and 18-month outcrossed
AβPP/PS1 mice and 8- and 12-month inbred C57BL/6 mice. Bars represent means ± SE.
Kruskal-Wallis test: plaque burden: p < 0.01. Post hoc Mann-Whitney tests of plaque
burden, *p < 0.05**, p < 0.01. Plaque deposition analyses: 12 months outcrossed, n = 5 mice
(6 sections per mouse); 18 months outcrossed, n = 8 mice (6 sections per mouse); 8 months
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inbred C57BL/6, n = 3 mice (6 sections per mouse); 12 months inbred C57BL/6, n = 6 mice
(4–6 sections per mouse). (C-F) Representative fluorescent images of Thioflavin S -stained
sections from the AβPP/PS1 cortex at (C) 12 months in outcrossed mice, (D) 18 months in
outcrossed mice, (E) 8 months in inbred C57BL/6 mice, and (F) 12 months in inbred
C57BL/6 mice. Bright puncta indicate Thioflavin S -reactive amyloid deposits. Scale bars =
200 µm.
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Fig. 5.
Measurements of animal survival, PS1 levels, AβPP levels, and AβPP processing. (A)
Kaplan-Meier curve showing cumulative survival percentage for outcrossed WT and AβPP/
PS1 mice up to 18 months. Symbols represent cumulative percent of animals surviving to
each month. Mantel-Haenszel log-rank test: p = 0.61. Animal survival analysis: WT, n = 83
mice (9 deaths total); AβPP/PS1, n = 81 mice (11 deaths total). Immunoblots of (B) full
length (FL) AβPP, (C) soluble AβPPα (sAβPPα), (D) AβPP β-C-terminal fragment (β-
CTF) and presenilin-1 (PS1), (E) soluble Aβ (sAβ), and (F) insoluble Aβ levels in
outcrossed WT and AβPP/PS1 mice on outcrossed at 12 and 18 months and inbred C57BL/
6WT and AβPP/PS1 at 8 and 12 months. HSP70 and actin levels are shown as loading
controls. Numbers on left of immunoblots represent approximate molecular weights (kDa).
(G) Quantification of non-amyloidogenic pathway including full length AβPP and sAβPPα
levels normalized to respective loading controls. Bars represent means ± SE. Kruskal-Wallis
test: Full length AβPP: p < 0.001; sAβPPα: no significance, p > 0.05. Post hoc Mann-
Whitney tests, **p < 0.01, ***p < 0.001. Full length AβPP analysis: n = 3 mice/group.
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sAβPPα analysis: outcrossed mice: 12M, n= 9 mice; 18M, n = 3 mice; inbred C57BL/6:
8M, n = 3 mice; 12M, n = 16 mice. (H) Quantification of amyloidogenic pathway, including
β-CTF, PS1, sAβ, and insoluble Aβ normalized to respective loading controls, when
possible. Bars represent means ± SE. Kruskal-Wallis test: PS1: no significance, p > 0.05; β-
CTF: no significance, p > 0.05; sAβ: p < 0.05; insoluble Aβ: p < 0.05. Post hoc Mann-
Whitney tests, *p < 0.05, **p < 0.01. PS1, β-CTF, sAβ, and insoluble Aβ analysis: n = 3
mice/group.
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Table 1
Primary antibodies
Antibody Name Immunogen Source, Catalog No. Species
AβPP (6E10) Aβ peptide residues 1–17 Millipore, MAB1560 Mouse monoclonal
AβPP, C-term AβPP residues 695, 751, 770 Sigma-Aldrich, A8717 Rabbit polyclonal
Presenilin 1 Residues around V293 Cell Signaling, 3622 Rabbit polyclonal
HSP70 (5A5) HSP70 residues 122–264 Abcam, 2787 Mouse monoclonal
Actin (C4) Actin residues 50–70 Millipore, MAB1501R Mouse monoclonal
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Table 2
Brain and body weight at 18 months
Genotype Brain
Weight (g)
Body
Weight (g)
(Brain/Body
Ratio)×100
WT 0.50 ± 0.01 51.7 ± 2.6 0.99 ± 0.05
AβPP/PS1 0.50 ± 0.01 51.4 ± 2.8 1.01 ± 0.07
Student's t-test p = 0.97 p = 0.94 p = 0.81
Values represent means ± SE.
WT, n = 13 mice; AβPP/PS1, n = 10 mice.
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